"HemoDefend IDE..filed by the end of this year..with potential approval in 2020.

"Switzerland with hopefully a pending assignment of reimbursement value..

"So in 2020..we expect to Poland will be a solid contributor to overall sales

"And that is expected to conclude by year end(2019). Once that -- once the study is done, the investigators believe that they will have analysis of their data and presentation of their data in mid-2020.

"approximately 4% of patients will have an acute cardiac event due to their underlying cardiac disease or underlying comorbid disease that will require either urgent or emergent cardiac surgery.

"savings of approximately $5,000 per case.....

"..we are aggressively pursuing expansion of our label based on data that were observed in Hamburg.

"..he was basically just shocked by the traumatic improvement he saw in terms of patients bleeding.

"..two separate presentations focused on early small studies using the checkpoint inhibitor pembrolizumab

(Keytruda) in patients who appear to be losing their response to CAR T cells

https://ascopost.com/issues/december-25-2018/combining-a-checkpoint-inhibitor-with-car-t-cell-therapy-may-augment-immune-response/



Acute kidney injury often seen with checkpoint inhibitor use


"The researchers found that overall, 17 percent of patients receiving checkpoint inhibitor therapy experienced AKI


https://medicalxpress.com/news/2019-11-acute-kidney-injury-checkpoint-inhibitor.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter

I read that when Fre' acquired them, Nx had reported Q2 rev of 96m and had os of 66m shares.
Fre' paid $30/sh.

Bertha, from your link..

JOINT TRAUMA SYSTEM CLINICAL PRACTICE GUIDELINE

Since 2010, the NxStage® System OneT M (NxStage Medical, Lawrence, MA) has been deployed to Craig Joint
Theater Hospital, Bagram Airfield, Afghanistan.

Acute kidney injury after combat trauma occurs in up to 34.3% of the most critically injured patients, usually
within the first 2 days after injury.1

..rapid evacuation out of
theater ensured that the complications of AKI (including hyperkalemia) occurred further up the evacuation chain
(Role 3-4), where renal replacement therapy (RRT) was often available.2

As a consequence, AKI and life threatening hyperkalemia may be encountered at
Role 1-3 facilities more frequently, where RRT is limited or non-existent.

Unapproved (i.e., “off-label”) uses of FDA-approved products are extremely common in American medicine and
are usually not subject to any special regulations.
***************************
FROM YAHOO BOARD (from Greg, 15 hours ago)

US Air Force, Contract Award Dollar Amount:$2,959,747. What stands out in the August 2016 PR from the company is " “These potassium binding polymers represent an entirely new product category for the company. " Also, “Our goal is to provide field medics with easy-to-administer solutions to acutely treat and stabilize wounded warfighters suffering from severe hyperkalemia as a result of massive trauma, burn injury, kidney failure, blood transfusions, and other conditions. These strategies could enable prolonged field care, particularly in far-forward situations where rapid evacuation is neither safe nor feasible. As a simpler, more rapid, and logistically friendly alternative to dialysis, we also envision our technology being used in emergency room or hospitalized patients with severe hyperkalemia, and helping victims of bombings, earthquakes, landslides and other mass casualty situations.”

Does that threaten some Fresenius business? Hopefully the company will PR this contract soon.

***********************************
Answer to Greg's question:

NxStage® System One™

Fresenius Medical Care has successfully completed its merger with NxStage Medical, Inc.


https://www.nxstage.com/hcp/products/systemone/

************************
" the first and only truly portable hemodialysis system cleared for home use in the United States, including solo hemodialysis during ...

https://www.nxstage.com/patients/system-one/

*********************
Will the "US Air Force" be buying from Fresenius or directly from ctso?

This shareholder would like to know. Hey, Esk', can you find that out for me?

also, ask them "is Fresenius selling to other militaries besides USA, where ctso has been approved?"
The German military, etc.? Thanks, Esk'.

AHA 2019 Heart Disease and Stroke Statistics
Feb 19, 2019

"..and 335,000 recurrent coronary events."

#4 "In the United States in 2019, coronary events are expected to occur in about 1,055,000 individuals, including 720,000 new and 335,000 recurrent coronary events.

Nice #s whether filters sales or cost saving to hospitals??
https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2019/02/15/14/39/aha-2019-heart-disease-and-stroke-statistics
******************************
Assume most of the 335K are using blood thinners

It just might be that if a b'thinner company could advertise that, in case of emer. surgery, their product can be removed on site mucho rapido, then their (and ctso) sales would benefit.

Your thoughts, Pears', Esk'? Either of you on b'thinners?

*******************************

October 4, 2019

Dr. Joerg Scheier, MD, Senior Medical Director of CytoSorbents Europe, stated, "These results are a prime example of the excellence of translational medicine in the CytoSorb user community, where ideas that target major unmet medical needs have become reality....in many different application areas.

"CytoSorb is more than a product. It is an innovation engine that is helping to change medicine."

"Ticagrelor (a platelet P2Y12 inhibitor; Brilinta®, Brilique® - Astra Zeneca) is one of the most commonly prescribed antithrombotic..

"There is currently no approved reversal agent for P2Y12 inhibitors in emergency cardiothoracic surgery patients,
creating a significant unmet need as RECOGNIZED by the U.S. Food and Drug Administration (FDA).
********************************


Sept. 25, 2019

"Patients treated with standard of care and CytoSorb had a statistically significant reduction in 28-day all-cause mortality compared to standard of care alone (53% vs 72% control, p<0.04), based on the sIPTW analysis. In addition, observed 28-day all-cause mortality in the CytoSorb treatment group was significantly lower than the predicted mortality (48% observed vs 75% predicted, p<0.001), based on SOFA score."

"95% of Medicare part D patients pay less than $1.50/day for Brlinta(ticagrelor)

Also for Afib (clots) and ischemic strokes. Other indications?

Those people sometimes wreck their car & need emergency surgery too.

"interrupt therapy with BRILINTA for 5 days prior to surgery...
may also prevent blood clots after certain heart surgeries (such as stent placement)."


I wonder if they could use our filter in the dental office? Nahhhhhh.

Any news about ctso and other blood thinners?

What a lame reply, esk'
**********************
btw
2 -3 years? The coast is 4 hours from here.

Just an hour ago I watched a train go thru loaded with mili. equipment.

I hope its not going to a port.

"..during the pregame show of TN Football.."

Eskay, a Tennessee fan? That explains everything. Football "portfolio"having a tough time the last few years?

I hope yourratalkin'boutem Titans.


Go Big Orange!
Lost to Georgia State University located in downtown Atlanta near the union mission.
(But trounced Chattanooga Poultry Institute 45 - 0!!!!!)

1 -3 record, facing UGA (#3) next? How are you going to bet on your orange beads?

Surely you know why Tennessee fans wear orange......

biotech,
Over target. Lotta flak.

The Rory Staunton Foundation For Sepsis Prevention

https://rorystauntonfoundationforsepsis.org/category/blog/

????

$CTSO filed SEC form 4: Chief Medical Officer Mortensen Eric R.:
Bought 12200 of Common Stock at price 0 on 2019-07-22. sec.gov/Archives/edgar/data...

filed SEC form 4: President and CEO Chan Phillip P.:
Bought 60000 of Common Stock at price 0 on 2019-07-22.


filed SEC form 4: Chief Operating Officer Capponi Vincent:
Bought 54100 of Common Stock at price 0 on 2019-07-22. sec.gov/Archives/edgar/data...


(As of 07/25/2019 11:08 AM ET)
https://www.marketbeat.com/stocks/NASDAQ/CTSO/?RegistrationCode=SocialMedia-StockTwits&utm_source=GeneralSocialMedia&utm_medium=Social


Wall St is expecting 6.30 revenue for $CTSO Q2 [Reporting 08/01 AMC]
https://www.estimize.com/ctso/fq2-2019?metric_name=revenue&chart=historical

from here
https://stocktwits.com/symbol/CTSO

First ever state sepsis regulation in US tied to lower death rates

https://medicalxpress.com/news/2019-07-state-sepsis-tied-death.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter

Caesar????

He came, he typed, he slipped out the back door.

The evil that men type lives after them;
The good is oft interred with their bones;
So let it be with Caesar.

What gives?

Up about 17% in the last month, since June 12.

Any idea?

Thanks

CAR-T has competition - NK cells, for one (eg., INMB, AFMD, KIADF, NK) and synthetic DNA vaccines is another.

“We are excited by the durable complete responses seen in patients with highly refractory disease safely treated with off-the-shelf haNK or aNK -- to date over 511 infusions of haNK cell therapy have been administered, without any patient requiring hospitalization or resulting in cytokine release syndrome,” said Patrick Soon-Shiong, M.D.

NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients

https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-announces-durable-complete-responses-multiple-advanced?field_nir_news_date_value[min]=2019

https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-launches-first-human-targeted-nk-phase-i-clinical?field_nir_news_date_value[min]=2019

https://www.technologynetworks.com/biopharma/news/synthetic-dna-vaccine-shows-promise-for-cancer-immunotherapy-310101

RESEARCH:

International team identifies potential therapeutic target for sepsis

(more articles at the bottom)

https://medicalxpress.com/news/2019-05-international-team-potential-therapeutic-sepsis.html?utm_source=nwletter&utm_medium=email&utm_campaign=daily-nwletter

siLverback,

They can measure cytokines. But who can do it the fastest in critical situations?

https://www.google.com/search?source=hp&ei=KmzxXNyqDdHktQWxgq7YBg&q=company+measures+cytokines&oq=company+measures+cytokines&gs_l=psy-ab.12..33i160.1392.9363..10997...0.0..0.105.2003.23j3......0....1..gws-wiz.......0i131j0j0i70i249j0i22i30j0i22i10i30.Tet6rAPOUKc

Mesoblast’s lead product candidate, remestemcel-L, is an investigational therapy comprising culture expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. It is
administered to patients in a series of intravenous infusions. Remestemcel-L has demonstrated
immunomodulatory properties to counteract the inflammatory processes that are implicated in aGVHD
by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

http://investorsmedia.mesoblast.com/static-files/4232b4cb-8942-476b-b002-cda7e3c42cc6

Spare change, Mr. June?

"Carl June, the pioneering CAR-T expert, is also joining its scientific advisory board."

T cell experts at Kiadis bag CytoSen’s NK cell tech, plotting a dual cancer killing approach with tips from Carl June

https://endpts.com/t-cell-experts-at-kiadis-bag-cytosens-nk-cell-tech-plotting-a-dual-cancer-killing-approach-with-tips-from-carl-june/


US ticker KIADF

An estimated 80,000 Americans died of flu and its complications last season.

The CDC is estimating that flu-related deaths this season in the range of 35,000 to 55,000.
**********************************

sickle cell Stem Cells from Half-Matched Donors in New Approach Reported to Cure 7 Sickle Cell Patients

https://sicklecellanemianews.com/2018/05/08/stem-cells-from-half-matched-donors-cure-sickle-cell-adult-patients-study-reports/

https://www.nhlbi.nih.gov/news/2019/sickle-cell-patients-recovery-after-gene-therapy-heightens-hopes-cure
**********************************

Bubble Boy cure

Rare 'Bubble Boy Disease' Likely Cured with New Gene Therapy

https://www.livescience.com/65270-bubble-boy-disease-gene-therapy.html

***************************
Q: Does NK cell anti-cancer therapy entail the side effects one encounters with CAR-T ? Hey, Jones?

Additional comments? From yahoo board -

"Preliminary Annual Proxy (PRE 14A): CTSO wants to double authorized common shares from 50M to 100M (Proposal 2) and increase the authorized shares for equity incentive plan by 6M (1.8x) from 7.4M to 13.4M (Proposal 3). Robert Shipley's Trust still has not sold a share, and Black Rock is still a beneficial owner (first disclosed on 13G filed on 02/08/2019).

"Obviously, doubling the common share count is the most interesting even though there's supposedly no immediate plan to issue any new shares.
*****************

"$5M in Term B loans from Western Alliance Bank: There should have at least been an 8-K by now if CTSO opted for the loans, so I am surprised that CTSO seems to have passed on taking on the additional debt. I am quite certain CTSO met all the required qualifications / tests, so that must mean either they simply did not want it or maybe they've received some kind of extension and are still negotiating with the bank.

"Loan principal repayments must begin on Nov. 1st without the Term B, so that will eat up additional cash flow. We should find out for certain about the Term B with the 10-Q for Q1 2019 in about ~30 days.

"Given that CTSO expects to only have enough funding to operate into 2020, we should probably fully expect CTSO to sell more equity before unless product sales really start going nuts.

"Given the latest annual proxy to double the authorized shares and the ongoing presentations at investor conferences from the analysts either covering CTSO or from entities that have participated in underwriting and managing past equity offerings (e.g., HC Wainwright), it seems like CTSO is gearing up to do another private placement offering for its funding needs.
***************************

17 days ago
"Per the re-worked agreement last year, I expect CTSO to opt for the $5M in Term B loans from Western Alliance Bank today or tomorrow. The deadline is Sunday, March 31, 2019, so Friday is the last business day before the deadline. Opting for the Term B loans will give CTSO another 6-month extension before repayment needs to begin in earnest (May 1, 2020 vs. November 1, 2019). Opting for the Term B also means a second success fee (= $318.5K = 6.37% of $5M) will be triggered if / when CTSO's stock price hits $11.985 (= 1.7 x $7.05) for 5 successive business days; CTSO will almost certainly pay this fee with common shares like it did for the first success fee. Per the 2018 10-K, as of December 31, 2018, the effective interest rate on the first $10M Term A loan is 9.16%; thus, if the Fed

Know any doctors in Switzerland? Call'em.
They already ok'd a code.
I was curious about when they will announce reimburs' percentage.
It's supposed to happen in 2019.

https://mediclever.com/medical-device-reimbursement-switzerland.php

Sept.2014
Healthcare referendum rejected: Switzerland will not change their private insurance company system to a single national insurance provider

(hmmmmmm)

"The private nature of the public Swiss insurance, as argued by the Swiss Federal Assembly, incentivizes the insurers to control reimbursements efficiently, be sensitive to patient satisfaction, and to devise innovative cost models in order to remain competitive and retain clients.

https://www.tforg.com/how-we-think/sweetspot-blog/2015/10/30/healthcare-referendum-rejected-switzerland-will-not-change-their-private-insurance-company-system-to-a-single-national-insurance-provider/
*****************************

Clarifications about the coding of CAR-T cell therapy in Switzerland

https://mtrconsult.com/news/clarifications-about-coding-car-t-cell-therapy-switzerland
*****************************

AUSTRIA

20 months ago, August, 2017. (I think things have changes since then.)

Extracorporeal cytokine adsorption therapy is currently not recommended for inclusion into the benefit catalogue in Austria for patients with sepsis and SIRS

"However, LBI-HTA noted that there is a potential evidence for further evaluation:..."

https://mtrconsult.com/news/extracorporeal-cytokine-adsorption-therapy-currently-not-recommended-inclusion-benefit

from Yahoo board

https://docs.google.com/spreadsheets/d/1rc_zFvSauYIspP3S-YBkYUOz19bu0PytXCMjUE-owdE/edit#gid=141253284

"Israel has a well-developed system for prioritizing coverage of new technologies within an annual overall budget set by the Cabinet (which includes Parliament members from the ruling parties).5 Proposals for additions are solicited and received from pharmaceutical companies, medical specialty societies, and others.

The Ministry of Health then assesses the costs and benefits of the proposed additions, and a public commission combines the technical input with broader considerations to prepare a set of recommendations. These are usually adopted by the Ministry and subsequently by the Cabinet.

https://international.commonwealthfund.org/countries/israel/
*************************

March 26, 2019

The Jerusalem Post

SEPSIS INCREASINGLY SEEN AS WORLD THREAT

https://www.jpost.com/Business-and-Innovation/Health-and-Science/Sepsis-increasingly-seen-as-world-threat-467492

will Israel reimburse immediately? Is CTSO now in their "Healthcare Basket"?

Googled: Israel healthcare reimbursement medical device

"Israel’s Reimbursement System is called “The Healthcare Basket.” It includes all the services, medications, supplies and medical equipment that the insured is entitled to receive according to the National Health Insurance Law.

"Local distributors are looking for innovative healthcare technologies that help reduce cost and improve patients' healing prospects.... Israeli healthcare facilities are modern and are open to adopting new, cost-effective technologies and procedures.....Other best sales prospects include minimally invasive surgical...cost-saving single use products..Israel has a growing elderly population and limited resources. As a result, the most significant demand is for cost-saving products and for products that help patients monitor their health at home.

"The average time it takes to obtain a market approval from the Ministry of Health is 120 days.
*********************
Reimbursement

"The National Health Insurance Law describes the following fields of service to be included in the healthcare basket for which the health funds (HMOs) are responsible:

Diagnosis, consultation and medical treatment
Medications according to a list, some of which are provided only for a particular indication
Hospitalization in a general hospital
Rehabilitation, including hospitalization
Accessories and medical supplies
Medical services in the work place

Procurement & Tenders

The Ministry of Health, its group purchasing organization – SAREL, and the four HMOs publish procurement requests and tenders on their websites. Tenders are published in the Hebrew language. U.S. companies that wish to participate would be required to engage with an Israeli partner.

Ministry of Health current tenders

SAREL: http://www.sarel.co.il/auction/

Clalit HMO Tenders

Maccabi Health Services Tenders
*****************
Trade Events

Name of Event: The Medical and Health-Care Device Development

Date: November 6, 2018

Location: Avenue Convention and Events Center, Airport City, Israel Website: https://10times.com/meditech-tel-aviv-yafo

Name of Event: Innovations in Cardiovascular Interventions (ICI) Meeting

Date: December 2-4, 2018

Location: Tel Aviv

Website: http://icimeeting.com/

Name of Event: Biomed Israel 2019

Date: May 2019

Location: Tel Aviv

Website: http://biomed.kenes-exhibitions.com
******************************
https://2016.export.gov/industry/health/healthcareresourceguide/eg_main_108590.asp
************
Innovation Award Competition(Cardio)
http://icimeeting.com/

TLRY, yep, they were really high, then they got smoked.
But their market appears to be on fire.
Maybe they'll get on a roll and rise from the ashes.

I just got this from a friend. What would you tell her, point by point?

"Hey –

I met with my investment guy today and we talked about cytosorb. He said often a stock that tanks quickly either has management problems or something they were anticipated didn’t pan out. He also said it could be people on the board of this company sits on the board of another company and fleecing this company??? I think that is what he said.

I am kind of anxious to see things going in the right direction.

Take care,

-------"

Know any military veterans having a bad time of it?
Tonix Pharmaceuticals..... lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. Breakthrough desig' by FDA.

Biotech Stocks Tumble as FDA Commissioner Gottlieb to Resign

https://www.bloomberg.com/news/articles/2019-03-05/biotech-index-crashes-on-report-that-fda-s-gottlieb-is-resigning
**********

I hope the departure of ‘tech-savvy’ Gottlieb won’t undo progress at the FDA

https://www.statnews.com/2019/03/07/tech-savvy-scott-gottlieb-forward-looking-fda/
*************

Gottlieb’s replacement? A roundup of likely, possible, and you-never-know contenders

https://www.statnews.com/2019/03/07/gottliebs-replacement-a-roundup-of-likely-possible-and-you-never-know-contenders/

The Indian Navy is one of the largest navies in the world,[2] and as of January 2018 possesses:

1 aircraft carrier, 1 amphibious transport dock, 8 Landing ship tanks, 11

destroyers, 13 frigates, 1 nuclear-powered attack submarine,1 Ballistic

missile submarine, 14 conventionally-powered attack submarines, 22

corvettes, 1 mine countermeasure vessels, 10 large offshore patrol vessels,

4 fleet tankers and various auxiliary vessels and small patrol boats

"..antibiotics..does combo treatment with CTSO benefit care of patient due to reduced time and potency of antibiotics?"

That makes sense to me, Burnt.

The “good” bacteria, your gut microbiota, are made up by over 1,000 different species and subspecies of bacteria that live in your intestines. They are a diverse community of bacteria helps you to break down food, synthesize various nutrients, keep harmful substances from entering your body, and strengthens your immune system. When the community is disrupted, it can quickly become unbalanced and creates a greater risk for disease and inflammation.

https://wellseek.co/2016/12/10/heal-gut-health-antibiotics/

Antibiotics have the ability to halt infectious diseases that were once debilitating or deadly. However, one of the unfortunate side effects is its negative impact on gut health.

.....overuse doesn’t just lead to drug-resistant superbugs, it may also permanently wipe out the body’s good bacteria.

Good bacteria in the gut help people in many ways, including helping make vitamins and boosting immunity.
*************************************
post-antibiotics > probiotics/fermented foods

CAREGIVER ALERT
Delaying or withholding antibiotics for over-65s with urinary infection linked to sepsis

https://eurekalert.org/pub_releases/2019-02/b-dow022619.php

(From real world experience - if they overmedicate for UTI, it can open the door for C-Dif.)
*************************************

So, from a privately held small innovator

A simple blood test for accurately distinguishing between bacterial and viral infection
https://www.me-med.com/memed-bv
*************
The crisis of antibiotic misuse - both for overuse when treating a non-bacterial disease,

such as a viral infection for which antibiotics are ineffective,

and to underuse in cases of bacterial disease for which antibiotic treatment was delayed or not given and would have benefited the patient.

https://www.me-med.com/the-crisis-of-antibiotic-misuse

Hello, Chen.

Might CTSO get into the liquid biopsy market?

"The researchers developed the new device to use size to separate tumor cells from blood.

“Using size differences to separate cell types within a fluid is much easier than affinity separation which uses ‘sticky’ tags that capture the right cell type as it goes by,” said Papautsky.

“Affinity separation also requires a lot of advanced purification work which size separation techniques don’t need....separate cancer cells from blood as it passes through “microchannels” formed in plastic.

https://www.genengnews.com/featured/liquid-biopsies-become-cheap-and-easy-with-new-microfluidic-device/?utm_medium=newsletter&utm_source=GEN%20Daily%20News%20Highlights&utm_content=01&utm_campaign=GEN%20Daily%20News%20Highlights_20190226&ajs_uid=3781H8231356A1W&oly_enc_id=3781H8231356A1W&ajs_trait_oebid=9675B9130356B7S

Found only 2 listed companies focusing on liquid biopsies
GH and EPGNF

This is great. I've been waiting for this.

Savings "With full reimbursement" :

€ 3,211 per patient "per patient" =

$3,649.67 United States Dollars.

"..cost saving that is a great additional benefit in addition to the positive clinical effects we see."

and this is just for infectious endocarditis.

I'd like to see some #s other applications, not just infectious endocarditis; or for the whole enchilada.

In addition to "Reducing the length of ICU stays also opens up additional financial opportunities for hospitals: More patients can be treated, as the availability of intensive care beds often creates a bottleneck in cardiac surgery.

T2Biosystems (TTOO), FDA approved

"The T2Bacteria® Panel is the first and only FDA-cleared test to identify sepsis-causing bacteria directly from whole blood without the wait for blood culture.....Species identification in hours instead of days

https://www.t2biosystems.com/products-technology/t2bacteria-panel/
122% qrtly rev'growth(yoy)

Would (1) Hemodefend complement or overlap at all with (2) CERS?

(1) "RBC filter for removal of contaminants such as antibodies, free hemoglobin, cytokines, and bioactive lipids in packed red blood cells."

(2) "The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood.
http://www.cerus.com/
$60M revs(ttm), 68% institutions

costs of sepsis

https://www.google.com/search?q=Costs+of+sepsis+in+ICUs&rlz=1C1CAFB_enUS681US681&oq=Costs+of+sepsis+in+ICUs&aqs=chrome..69i57.9475j0j7&sourceid=chrome&ie=UTF-8

Right down our alley

Lucy Turpin Communications GmbH
https://www.lucyturpin.de/en/branchen/

(1) Markets........sepsis

"Medical Devices, Life Sciences, Pharma or Healthcare – We are on the Pulse of Time.
With the experience we’ve gained to-date, we are conversant, inter alia with the issues regarding minimally-invasive aortic valve replacement, or one-step percutaneous tracheotomy, or >>>the DANGERS OF SEPSIS.<<<<

However, to add your solutions to the health sector agendas of the people who count, we can offer more. Because we work the comprehensive health sector ecosystem including regulatory, multi-stage certification, the insurer and political environments, we know that these instances and institutions all need to be incorporated into successful communications planning – that’s why we can claim that we’ve got our finger on the pulse of the industry.

(2) Clients- definitely into heart surgery too (scroll down)

Jenavalve: Aortic valve implantation: A pocket-size guide shows how it’s done.

Cook Medical: Aortic aneurysms are a silent killer – A cardiac surgeon explains in a video interview.


https://www.lucyturpin.de/en/customers/

American Society for Blood and Marrow Transplantation Announces Consensus
Grading of CART Toxicities

https://higherlogicdownload.s3.amazonaws.com/ASBMT/43a1f41f-55cb-4c97-9e78-c03e867db505/UploadedImages/2_1_19_CAR_T_Press_Announcement.pdf

MEDICARE
"KEEP AN EYE OUT FOR CMS’S CAR-T PLAN — The agency gave itself until Feb. 16 to make a proposed national coverage determination for CAR-T cell therapies, laying out how Medicare programs should cover and reimburse for the nearly half-million dollar cancer drugs that are touted as one-time treatments.

It’s virtually certain that CMS will propose coverage with evidence development, said John Leppard of Washington Analysis. If so, Medicare programs nationwide would have to cover CAR-T but the agency would also require ongoing studies and a national registry.
https://www.politico.com/newsletters/prescription-pulse/2019/02/11/tuesdays-a-big-day-for-drug-pricing-and-fda-507587